(VIANEWS) – Shares of Pacific Biosciences of California (NASDAQ: PACB) dropped by a staggering 16.09% in 7 days from $6.08 to $5.10 at 12:15 EST on Monday, after four sequential sessions in a row of losses. NASDAQ is rising 0.44% to $10,915.33, after four sequential sessions in a row of losses.

Pacific Biosciences of California’s last close was $5.27, 83.05% below its 52-week high of $31.10.

About Pacific Biosciences of California

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides PacBio's Systems, which conduct, monitor, and analyse biochemical sequencing reactions; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. The company serves research institutions; commercial laboratories; genome centers; public health labs, hospitals and clinical research institutes, contract research organizations, and academic institutions; pharmaceutical companies; and agricultural companies. It markets its products through a direct sales force in North America and Europe, as well as through distribution partners in Asia, Europe, the Middle East, Africa, and Latin America. Pacific Biosciences of California, Inc. has a development and commercialization agreement with Invitae Corporation. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.

Earnings Per Share

As for profitability, Pacific Biosciences of California has a trailing twelve months EPS of $-0.34.

Return on Equity (TTM)

Pacific Biosciences of California’s ROE is -34.53%.

Volume

Today’s last reported volume for Pacific Biosciences of California is 2656627 which is 66.15% below its average volume of 7849461.

Pacific Biosciences of California’s Sales

Pacific Biosciences of California’s sales growth is 16.6% for the ongoing quarter and 27.6% for the next. The company’s growth estimates for the current quarter and the next is a negative 52.4% and a negative 500%, respectively.

Pacific Biosciences of California’s Revenue

Year-on-year quarterly revenue growth grew by 14.4%, now sitting on 134.69M for the twelve trailing months.

Volatility

Pacific Biosciences of California’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.41%, a negative 1.02%, and a positive 6.66%, respectively.

Pacific Biosciences of California’s highest amplitude of average volatility was 6.27% (last week), 6.91% (last month), and 6.66% (last quarter), respectively.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Pacific Biosciences of California’s stock is considered to be overbought (>=80).

Pacific Biosciences of California’s Stock Yearly Top and Bottom Value

Pacific Biosciences of California’s stock is valued at $5.10 at 12:15 EST, way below its 52-week high of $31.10 and way higher than its 52-week low of $3.85.

Pacific Biosciences of California’s Moving Average

Pacific Biosciences of California’s value is way below its 50-day moving average of $5.88 and way under its 200-day moving average of $8.93.

More news about Pacific Biosciences of California (PACB).

LEAVE A REPLY

Please enter your comment!
Please enter your name here